Ichthyosis Clinical Trial
OBJECTIVES: I. Compare the safety and efficacy of monolaurin cream versus a placebo vehicle
cream in suppressing the signs of nonbullous congenital ichthyosiform erythroderma.
II. Assess the incidence of posttreatment rebound or recrudescence in patients with
congenital ichthyosis.
III. Evaluate the long term safety of monolaurin cream with whole body application in these
patients.
PROTOCOL OUTLINE: This is a three month, randomized, double blind, placebo controlled study
followed by a nine month, open label, rollover study.
Patients are treated either with a placebo vehicle cream or the study cream, monolaurin (15%
glyceryl monolaurate), for 3 months followed by a four week break. Medications are applied
uniformly twice daily (morning and at least 1 hour before bedtime). After this blinded
portion of the study, all patients are administered monolaurin cream for 9 months.
Patients are followed for 4 weeks after the last cream application.
Completion date provided represents the completion date of the grant per OOPD records
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03051347 -
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
|
N/A | |
Completed |
NCT00074685 -
National Registry for Ichthyosis and Related Disorders
|
||
Completed |
NCT03641261 -
Therapeutic Education Using an Internet Application in Hereditary Ichthyosis
|
N/A | |
Completed |
NCT03796052 -
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
|
N/A | |
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Active, not recruiting |
NCT05295732 -
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
|
Phase 3 | |
Terminated |
NCT02655861 -
A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
|
||
Recruiting |
NCT03464994 -
Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO)
|
N/A | |
Recruiting |
NCT03417856 -
Defining the Skin and Blood Biomarkers of Ichthyosis
|
||
Terminated |
NCT04697056 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
|
Phase 2 | |
Recruiting |
NCT06330350 -
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
|
||
Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
Not yet recruiting |
NCT06362447 -
Efficacy of Injectable Gentamicin in Hereditary Ichthyosis
|
Phase 2 | |
Active, not recruiting |
NCT04549792 -
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
|
Early Phase 1 |